BRAF and skin squamous cell carcinoma: Pharmacological treatments with BRAF inhibitor monotherapy (i.e., vemurafenib, dabrafenib, or encorafenib) have a higher risk of cSCC development [28] compared to combined BRAF/mitogen-activated protein kinase kinase (MEK) inhibitors [29].